291 results about "Glycolysis" patented technology

The invention belongs to the technical field of biology, and relates to an escherichia coli engineering strain for producing L-isoleucine through a methyl malic acid way as well as a construction method and application of the escherichia coli engineering strain. According to the invention, Escherichia coli BW25113 is used as a chassis strain, and a methyl malic acid synthase high-activity mutant gene cimA3.7, an isopropyl malic acid isomerase gene GsleuCD, a 3-isopropyl malic acid dehydrogenase gene AfleuB and a leucine dehydrogenase gene Lsleudh are over-expressed; a methyl malic acid absorption protein gene is over-expressed, and a branched chain amino acid transport system is modified to improve the exosome of the L-isoleucine; all methyl malic acid pathway related genes are integrated to a genome of a chassis strain, and a plasmid-free L-isoleucine production strain is constructed; the copy number of a key gene on a genome is optimized, and the yield of the engineering strain L-isoleucine is increased by introducing a non-oxidative glycolysis approach. The yield of the L-isoleucine after the engineering strain is fermented for 34 hours in a fermentation tank is 56.6 g / L.

The present invention addresses the problem of providing an improving agent for improving a stratum corneum barrier function without external replenishment with any moisturizing substance and a pharmaceutical composition containing said improving agent. The present invention provides: a stratum corneum barrier function improving agent which contains a glycolytic inhibitor as an active ingredient; the stratum corneum barrier function improving agent in which the glycolytic inhibitor is at least one selected from the group consisting of a glucose transporter inhibitor and a glucose competitive inhibitor; either of said stratum corneum barrier function improving agents having at least one selected from the group consisting of an inhibitory effect on the loss of skin moisture retention capacity and an inhibitory effect on skin permeability enhancement; and a pharmaceutical composition which contains any of said stratum corneum barrier function improving agents.

The invention belongs to the technical field of grease preparation, and particularly relates to a preparation method and application of diglyceride oil with a weight reducing effect. Comprising the following steps: firstly, adding grease into a basic nutrient solution, adding strains for fermentation, and filtering to obtain a glycolysis product; adding glycerol into the glycolysis product, carrying out lipase esterification reaction, and carrying out centrifugal separation to obtain an oil phase; the method comprises the following steps: degrading triglyceride by adopting dominant strain fermentation, then adding glycerol, and carrying out esterification reaction under the action of dominant compound lipase to obtain the diglyceride oil. According to the method, the 1, 3-diglyceride can be selectively generated, the proportion of dominant grease of the 1, 3-diglyceride can be increased, and research shows that the prepared diglyceride oil has good weight reduction and fat reduction effects and has a good application prospect.

The invention discloses a traditional Chinese medicine composition for treating aplastic anemia and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises active substances, and the active substances are prepared from, by weight, 6-12 parts of semen cuscutae, 6-12 parts of fructus psoraleae, 6-12 parts of fructus ligustri lucidi, 10-14 parts of radix rehmanniae recen, 4-12 parts of radix scutellariae, 4-12 parts of cortex phellodendri, 10-20 parts of poria cocos, 10-30 parts of radix codonopsis, 6-12 parts of rhizoma atractylodis macrocephalae stir-fried with bran and 2-10 parts of radix glycyrrhizae preparata. The traditional Chinese medicine composition is low in cost, high in AA treatment effect and free of toxic and side effects, and has the effects of tonifying kidney, replenishing essence, detoxifying, descending turbidity and the like; the therapeutic effect on AA can be achieved by adjusting glycolysis of macrophages.

The invention discloses a yarrowia lipolytica engineering strain with high yield of resveratrol as well as construction and application of the yarrowia lipolytica engineering strain, and belongs to the technical field of synthetic biology and metabolic engineering. The invention provides a yarrowia lipolytica engineering strain. A 4-coumaric acid-CoA ligase gene, a multi-copy resveratrol synthase gene, a transketolase 1 gene, a fusion gene of a histidine phosphate aminotransferase gene and a tyrosine ammonia lyase gene, a glycolytic pathway hexokinase gene, a 6-phosphofructokinase-1 gene and a phosphoglycerate kinase gene are integrated, so that the recombinant protein is obtained. According to the present invention, by using glucose as the substrate, the high yield of resveratrol can be achieved by using glucose as the substrate, the resveratrol yield during shake-flask culture fermentation can achieve 3.157 g / L, the resveratrol yield can be increased to 30.7 g / L during 5L-scale fed-batch fermentation, and the resveratrol yield can be increased to 30.7 g / L when the resveratrol yield is increased to 30.7 g / L when the resveratrol yield is increased to 30.7 g / L when the resveratrol yield is increased to 30.7 g / L; the maximum value is reported by the yarrowia lipolytica system at present.

An ultrasound-metabolic synergistic system for diagnosing SLN metastasis of breast cancer. A deep learning model based on grayscale ultrasound is constructed to predict SLN metastasis of breast cancer, and 9 grayscale deep features and 15 grayscale manual features associated with SLN metastasis are obtained. A matrix material based on two-dimensional material MXene / multi-walled carbon nanotubes improves the detection of small metabolic molecules in blood, and metabolomics analysis results show that this has certain potential in detecting SLN metastasis of breast cancer, while revealing metabolic pathways closely associated with metastasis, such as the glucose-alanine cycle and glycolysis, suggesting that alterations in relevant molecular pathways may underlie heterogeneous features in ultrasound radiomics. The combination of ultrasound omics and metabolomics further improves the diagnostic performance for SLN metastasis of breast cancer. Therefore, organic integration of the two serves the diagnosis of SLN metastasis of breast cancer, providing a new strategy and theoretical basis for the accurate diagnosis of SLN metastasis of breast cancer, and possesses practical clinical application values.

The invention discloses a rice large-scale metabolism regulator DGP1 and crop metabolism quality design. The invention finds that the structural domain of the rice DGP1 family protein TIGR01589 targets a plurality of metabolic enzymes and promotes the metabolic enzymes to be transferred to a cell nucleus; the structural domain also has an intervention effect on a light breathing pathway by changing the composition of a glycine decarboxylase compound in mitochondria. Based on a molecular mechanism of DGP1, a chimeric protein ST containing a conservative structural domain and coupled with a chloroplast positioning signal is designed, and genetic engineering modification of pakchoi is realized. The modification strategy not only can guide substrate flow of a central glycolysis pathway to flavonoid biosynthesis, but also can promote accumulation of saccharides derived from photosynthetic products in leaves.

The present invention relates to a process for depolymerizing a polyester feedstock comprising opaque PET, which comprises: a) a conditioning step; b) a step of glycolysis, operated at between 180 and 400° C., a residence time of from 0.1 to 10 h in the presence of diol; c) a diol separation step, at a temperature of between 100 and 250° C., a pressure lower than that of step b) and producing a diol effluent and an effluent rich in monomers; d) a step of separating into a heavy impurities effluent and a prepurified monomers effluent, at a temperature of less than 250° C. and a pressure of less than 0.001 MPa and a residence time of less than 10 min; e) a step of decolourizing the prepurified monomers effluent, by adsorption of a mixture comprising between 20% and 90% by weight of the prepurified monomers effluent and a solvent, at a temperature of between 100 and 200° C., a pressure of between 0.1 and 1.0 MPa and in the presence of at least one adsorbent.

The invention relates to the technical field of microbiology and food processing, in particular to pediococcus acidilactici and application of the pediococcus acidilactici in preparation of a brain-intestinal axis regulating efficacy metagen product.The high-activity pediococcus acidilactici DY-1 is separated out from natural fermentation pickles of super-polyselenium plant cardamine violifolia for the first time; the strain can be widely applied to fermentation of high-selenium plant-based food, can significantly promote glycolysis release of selenium-containing active substances, has good acid resistance, high protease activity and high lipase activity, can fully ferment plant-based fermentation raw materials, and has high yield. Glycolysis of macromolecular substances such as protein, saccharides and fat is facilitated, accumulation of active ingredients such as essential amino acid, unsaturated fatty acid, alkaloid and phenolic substances is promoted, and the edibility and functionality of the product are improved; and the organic selenium-rich metagen product prepared by sterilizing the fermentation mixture can synergistically improve human body cognition and emotion regulation regulated by microorganism-intestinal-brain axis.

The invention belongs to the field of biological medicine, and particularly relates to PGK1 K17 site succinylation modification and application. Experiments show that the 17-site lysine of the PGK1 protein has succinylation modification (PGK1 K17su), and the existence of the modification is confirmed through a specific succinylation modified antibody for the first time. Further, it is found that PGK1 K17su can weaken lung cancer cell oxidative phosphorylation and promote glycolysis metabolism by inhibiting lung cancer cell mitochondrial generation, and functional experiments prove that PGK1 K17 succinylation modification promotes proliferation and migration of lung cancer cells.

The present invention relates to a process for preparing bis-(2-hydroxyethyl) terephthalate by depolymerization of a plastic filler comprising PET, comprising: a) a step of depolymerization of the PET in the presence of a diol, so as to have a weight ratio between the diol and the PET of the plastic filler of between 0.3 and 8.0, said step a) comprising a reaction phase operated between 150 and 300°C, b) a step of evaporation of the BHET to produce a BHET-rich stream and a heavy impurity stream, step b) using an evaporator comprising an evaporation zone and a zone for withdrawing the heavy impurity stream, and a section for discharging the heavy impurity stream located downstream of the evaporator, the evaporator being operated at a pressure less than or equal to 0.0010 MPa,and in which the evaporation zone is operated between 120 and 300°C and the heavy impurity stream withdrawal zone and the heavy impurity stream discharge section at a temperature greater than 250°C and less than or equal to 300°C.,

The present invention discloses a method for preparing a recycled copolyester and a heat-shrinkable film thereof, belonging to the field of waste polyester recycling. The method utilizes technologies such as glycolysis and methanol transesterification of waste polyester to produce recycled dimethyl terephthalate, which is then transesterified with other modifying monomers and ethylene glycol, followed by polycondensation, to produce the recycled copolyester. Finally, the recycled copolyester is directly delivered to the extrusion dies via a melt delivery pipeline and a metering pump to produce the recycled polyester heat-shrinkable film. The recycled polyester heat-shrinkable film exhibits high shrinkage, excellent toughness, and transparency, while also achieving high-value recycling of waste polyester.

The invention discloses a lactococcus lactis recombinant bacterium for expressing cyclic diadenylate and application of the lactococcus lactis recombinant bacterium. Homologous DAC is introduced into lactococcus lactis NZ9000, PDE is knocked out to improve expression of cyclic diadenylate in lactic acid bacteria, and meanwhile, the yield of a cyclic diadenylate precursor ATP is increased by increasing the expression quantity of glycolysis key enzyme PFK; and the ldh gene is knocked out to reduce the accumulation of byproducts, so that the yield of the inner ring diadenylate of the lactic acid bacteria is further improved.

The invention discloses a self-assembled PROTAC nano material based on natural product mitochondria targeting, which is a nano particle prepared from mitochondria targeting molecules, a photosensitizer and PROTAC as raw materials through a nano precipitation method. The mitochondrial targeting molecule is berberine, the photosensitizer is hypericin, and the PROTAC is dBET57; the ratio of the amount of substance of the dBET57 to the amount of substance of the berberine is (1-10): (1-10), and the ratio of the amount of substance of the dBET57 to the amount of substance of the hypericin is (1-10): (1-10). The nano material can be used for blocking multiple energy metabolism pathways of tumor cells, including glycolysis and oxidative phosphorylation, meanwhile, mitochondria is damaged, ferroptosis is induced, and the anti-tumor capacity of pharmacodynamic molecules is improved; bRD4 in tumor cells and downstream carcinogenic protein c-Myc of the BRD4 can be efficiently degraded. The invention also discloses an application of the nano material in preparation of antitumor drugs.

The invention discloses application of a JMJD6-targeted reagent in preparation of a medicine for promoting myocardial cell proliferation. The medicine can promote myocardial cell proliferation after myocardial infarction and reduce the myocardial fibrosis scar area caused by myocardial infarction. AAV9 myocardial specific overexpression virus and JMJD6 myocardial specific knockout mice are utilized, and the positive effect of JMJD6 in promotion of P1 cardiac apex resection of newborn mice and regeneration and repair of injured hearts after myocardial infarction of adult mice is disclosed for the first time; the specific mechanism is that JMJD6 depends on the activity of histone demethylase, enrichment of active modification H4R3me2a and H3R2me2s in a PDK4 promoter region is removed, transcriptional expression of the H4R3me2a and the H3R2me2s is inhibited, an impaired heart energy substrate utilization mode is stimulated to be increased and converted from fatty acid oxidation energy supply to glycolysis oxidation energy supply, and then adult myocardial cell proliferation is effectively promoted. The regeneration and repair capability of the heart after myocardial infarction is greatly improved, and a new effective target spot is provided for clinical treatment of myocardial injury.

The invention discloses an application of nicotinamide adenine dinucleotide in preparation of a medicine for treating keloid, and by researching the pathophysiological mechanism of keloid, it is found that mechanical related fibroblasts of keloid patients have metabolic reprogramming changes. Fibroblast populations which are mainly pathogenic to keloid have metabolic reprogramming caused by mitochondrial dysfunction, especially glycolysis level enhancement in cells and lactic acid accumulation. The medicine, namely NAD +, capable of regulating and controlling keloid fibroblast glycolysis and mitochondrial metabolism is found and verified through cell and animal experiments, and NAD + inhibits development of keloid by improving mitochondrial dysfunction, reducing lactic acid accumulation and inhibiting fibroblast migration and collagen synthesis. According to the invention, NAD +, which is a common medicine with good safety, is applied to keloid for the first time, and the scheme has small toxic and side effects and also has positive effects on oxidation resistance, aging resistance and cancer resistance, so that a new scheme is provided for treating keloid by medicines.

This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 μM and stimulatory activity at 100 μM. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).

A method of generating a hematopoietic cell, including providing a source cell and treating the source cell with a metabolic regulator that directs the source cell to preferentially use glycolysis or oxidative phosphorylation and / or cholesterol biosynthesis, wherein the source cell is differentiated into a GPA+ erythroid cell or a CD45+ non-erythroid cell. In some examples, the source cell is selected from the group consisting of a hemogenic endothelial (HE) cell, a iPS cell such as a differentiating iPS cell, a cell directly reprogrammed to a known pre-cursor of a hematopoietic cell, a cell directly reprogrammed to a hematopoietic cell or precursor of a hematopoietic cell, a reprogrammed cell that is subsequently further reprogrammed to a hematopoietic cell or precursor of a hematopoietic cell, an adult hematopoietic cell derived from bone marrow or mobilized peripheral blood and a neonatal hematopoietic cell derived from cord blood or prenatal tissue (e.g. placenta). Some examples involve metabolically regulating a lipid biosynthesis pathway with an inhibitor of the lipid biosynthesis pathway or metabolically regulating a histone acetylation pathway with an inhibitor of the histone acetylation pathway.

The invention discloses a recombinant bacillus paralicheniformis and an application of the recombinant bacillus paralicheniformis in production of betaine. According to the invention, bacillus paralicheniformis Bp1 with heavy metal cadmium resistance is used as a chassis strain, and an de novo synthesis pathway which takes glucose as a substrate and synthesizes glycine betaine through glycolysis, glyoxylic acid pathway and glycine methylation pathway in sequence is established in the bacillus paralicheniformis, so that the survival rate of the glycine betaine in cadmium-polluted soil is increased; the effects of the microbial soil treating agent and the microbial fertilizer are improved, so that the growth of the plant-black nightshade with an enrichment effect on cadmium and the absorption of the black nightshade on the cadmium in the polluted soil are promoted.

The invention relates to the technical field of medicines, in particular to application of Wushan icaritin in preparation of medicines for treating liver cancer diseases. The Wushan icaritin can effectively reduce the expression of lactic acid content in the liver cancer stem cells, reduce the lactic acid modification level of the liver cancer stem cells, inhibit the glycolysis level of the liver cancer stem cells, reduce the number of the liver cancer stem cells in the S phase, and improve the survival rate of the liver cancer stem cells through multiple ways. The compound can inhibit malignant biological behaviors of liver cancer stem cells and slow down the liver cancer disease process, and can be used as a natural preparation for treating liver cancer diseases.

The process for converting poly (ethylene terephthalate) to terephthalic acid comprises: a glycolysis step in which poly (ethylene terephthalate) is reacted with ethylene glycol in the presence of a specific catalyst; a hydrolysis step in which the product of the glycolysis step is reacted with an alkali metal hydroxide to produce an alkali metal salt of terephthalic acid; and an acidification step in which the product of the hydrolysis step is acidified to produce a precipitate containing terephthalic acid. Each step of the process can be carried out at ambient pressure or near ambient pressure, and the process produces terephthalic acid in high yield and high purity.

The present invention relates to a complex comprising a polysaccharide conjugate, an anti-PD-L1 monoclonal antibody, and a PKM2 inhibitor. The complex of the present invention can accumulate and remain in tumor tissue, effectively stimulate dendritic cell maturation, alleviate the inhibitory immune microenvironment, and trigger a specific anti-tumor immune response. It can effectively inhibit the expression of PKM2, thereby inhibiting glycolysis in tumor tissue and providing a more favorable environment for T lymphocytes to infiltrate tumor tissue. The complex of the present invention is expected to enhance the therapeutic effect of RFA on patients with advanced HCC by reprogramming iRFA-induced tumor immunosuppression, and has great potential in improving the prognosis of patients with advanced HCC treated with RFA.

The invention relates to the technical field of osteoarthritis drugs, particularly discloses an application of DDX5-K45mRNA in preparation of drugs for treating and / or relieving osteoarthritis, and provides a drug delivery system for targeting chondrocytes at the same time, research finds that when DDX5-K45mRNA is added into the chondrocytes, the drug delivery system can be used for treating and / or relieving osteoarthritis. The medicine can restore DDX5-K45 lactic acid, block NF-kappa B inflammation signals, correct metabolic reprogramming (such as inhibition of abnormal glycolysis), and up-regulate cartilage protection factors such as COL2A1 and the like. The LNP is utilized to efficiently deliver DDX5-K45mRNA to cartilage cells, endogenous lactic acid modification defects are directly supplemented, the cartilage protection function of DDX5 is reconstructed, inflammatory response is inhibited, matrix degradation is reduced, the cartilage steady state is maintained fundamentally, and long-acting and safe OA treatment is achieved.

Quinones for use in therapeutic recovery, normalization and / or improvement of ATP in mitochondrial deficient cells, such as red blood cells, are disclosed. Particular examples are use in the treatment of erythrocystic diseases, especially in the treatment of erythrocyte metabolic defects, such as erythrocyte glycolysis defects. This treatment increases ATP in non-mitochondrial cells. Thus, the present invention relates to quinones for use in the treatment of diseases or conditions associated with or caused by a glycolytic deficiency in red blood cells.

The invention discloses an application of a PGK1 inhibitor in preparation of a medicine for treating MYC (myelodysplastic cancer) oncogene amplification type prostate cancer, it is found for the first time that PGK1 is a stable target for patent medicine, the PGK1 inhibitor NG-52 can effectively inhibit growth of MYC oncogene amplification type prostate cancer cells, and the target targets a glycolytic pathway, has small influence on aerobic respiratory metabolism of normal cells in a body, and can be used for preparing a medicine for treating MYC oncogene amplification type prostate cancer. The safety is higher; the mechanism of the target is different from that of current advanced prostate cancer chemotherapy drugs and endocrine therapy drugs, and the target has great potential of combined treatment with current first-line drugs, is easy to popularize and use clinically, and provides better prognosis for MYC gene amplification type prostate cancer patients.

The invention discloses antibacterial mouthwash as well as a preparation method and application thereof, and belongs to the technical field of daily chemical products. According to the invention, egg white lysozyme, ferulic acid and grape seed procyanidine are taken as core components, and the mouthwash with an efficient bacteriostatic effect is developed. And the antibacterial rates of streptococcus mutans and porphyromonas gingivalis are 96.88% and 96.30% respectively. Researches show that bacterial biofilms can be destroyed by using the mouthwash, and the biofilm quantity is reduced by 53.7% after the bacterial biofilms are treated for 24 hours; extracellular polysaccharide is inhibited, the content of water-insoluble glucan is reduced by 62.3%, and synthesis of a key cariogenic matrix is hindered; the acid production capacity is regulated and controlled, the pH change of 24-hour culture is only 1.50, and xylitol competitively inhibits glycolysis and cooperates with ferulic acid to block bacterial metabolism. The mouthwash prepared by the invention avoids the problem of enzyme activity inhibition of the ionic surfactant of the traditional mouthwash, takes effect more quickly, and provides a basis for developing natural, safe and efficient functional mouthwash.

The invention discloses application of CFB polypeptide as a target spot in preparation of diabetic nephropathy diagnosis and treatment medicines, and belongs to the technical field of biological medicines. The invention provides application of CFB (circulating fluid bed)-sourced polypeptide in preparation of a medicine for treating diabetic nephropathy and application of the CFB-sourced polypeptide as a possible target in development of a novel diabetic nephropathy biomarker. According to the invention, a complement factor B-derived polypeptide which is significantly up-regulated in diabetic nephropathy is found through deep peptidomics analysis; furthermore, a functional experiment proves that the polypeptide shows remarkable anti-fibrosis activity in kidney cells for the first time, the active oxygen level can be reduced, and an HIF-1 alpha / glycolytic pathway can be regulated and controlled.

The invention discloses application of an HIF1A inhibitor in preparation of a medicine for preventing and / or treating hypertrophic cardiomyopathy, and belongs to the field of biological medicine. For a rat model of spontaneous hypertrophic cardiomyopathy caused by MYH7B gene knockout, hypertrophic cardiomyopathy can be significantly relieved by intraperitoneal injection of the HIF1A inhibitor LW6, heart remodeling can be relieved, heart functions can be improved, and myocardial hypertrophy caused by silent MYH7B genes can be effectively resisted by using siRNA of mRNA transcribed by the HIF1A gene. The key mechanism of the HIF1A inhibitor for treating the hypertrophic cardiomyopathy is that the hypertrophic cardiomyopathy is prevented and treated by reducing the expression level of glycolysis key enzymes GLUT1, HK2 and the like, inhibiting the formation and accumulation of cardiac lactic acid and improving the ventricular remodeling of the hypertrophic cardiomyopathy. The results show that the HIF1A inhibitor can be used for treating and / or preventing the human hypertrophic cardiomyopathy and has the potential of being developed into the medicine for clinically preventing and treating the hypertrophic cardiomyopathy.

The invention discloses application of thiamine in preparation of a product for treating subclinical ketosis of dairy cows, and belongs to the field of biological medicines. Tests prove that compared with dairy cows suffering from subclinical ketosis (SCK), by adding thiamine, the content of beta-hydroxybutyric acid (BHBA), the number of bacteria in milk and the number of somatic cells can be remarkably reduced, and the milk yield, the milk fat content, the acetic acid content and the A / P ratio are remarkably increased; the microbial diversity of rumen and excrement of the dairy cow can be adjusted; a metabonomics result shows that metabolite up-regulated after the thiamine is added mainly focuses on pyruvic acid metabolism, glycolysis or gluconeogenesis, tyrosine metabolism, glycerophospholipid metabolism and biosynthetic pathways of phenylalanine, tyrosine and tryptophan. The conclusion is that when thiamine is added into the SCK dairy cow, synthesis and catabolism of BHBA of an organism can be effectively regulated and controlled by adjusting the content of succinyl-coenzyme A, then subclinical ketosis is relieved, rumen fermentation is promoted, and therefore the milk yield and the milk quality are improved.

The invention discloses a production method for improving the ring opening rate of monascus milovastatin, and belongs to the technical field of monascus rice production. According to the method, a monascus purpureus high-yield strain is selected and inoculated into a solid indica rice matrix containing a specific additive for fermentation after spore activation, and the matrix comprises 1, 5-p-coumaroylquinic acid, sodium acetate, sodium citrate, a thermally modified soybean protein isolate polysaccharide sulfate compound and other components. Wherein sodium acetate and sodium citrate can serve as short-chain fatty acid precursors, the activity of closed-loop lactonase is inhibited through pH regulation, and generation of lactone type products is reduced; 1, 5-p-coumaroylquinic acid activates the expression of a polyketide synthase gene cluster, so that the synthesis flux of the Monacolin K with an open-loop structure is improved; nicotinamide ribose enhances the electron transfer efficiency of glycolysis and TCA circulation, provides sufficient ATP for polyketone synthesis, and promotes synthesis of Monacolin K. The compound further strengthens the synthesis flux of secondary metabolites by changing the form of hyphae and continuously releasing a nitrogen / carbon source, and promotes intracellular products to be transferred to extracellular.